Fidaxomicin 200 mg + Placebo + Vancomycin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile
Conditions
Clostridium Difficile, Spinal Cord Injury
Trial Timeline
Feb 1, 2014 → Oct 1, 2016
NCT ID
NCT02355938About Fidaxomicin 200 mg + Placebo + Vancomycin
Fidaxomicin 200 mg + Placebo + Vancomycin is a approved stage product being developed by Merck for Clostridium Difficile. The current trial status is terminated. This product is registered under clinical trial identifier NCT02355938. Target conditions include Clostridium Difficile, Spinal Cord Injury.
What happened to similar drugs?
7 of 20 similar drugs in Clostridium Difficile were approved
Approved (7) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02355938 | Approved | Terminated |
Competing Products
20 competing products in Clostridium Difficile